Oncology Intelligence
Focused analysis of global oncology pipelines, immunotherapy breakthroughs, regulatory acceleration pathways and competitive strategy across major pharmaceutical markets.
Oncology remains the largest therapeutic category globally.
Immuno-oncology, ADCs, targeted therapies and combination regimens are redefining competitive positioning.
From Liposomes to ADCs: Breakthroughs of Novel Drug Delivery Systems in Cancer Therapy
July 16, 2026
Explore how liposomes, albumin-bound technologies, ADCs, and next-generation drug delivery systems are transforming cancer treatment through precision delivery and reduced toxicity.
Why Do Many Solid Tumor Treatments Still Rely on Infusion Therapy? The 2026 Landscape of Oncology Injection-Based Treatments
July 16, 2026
Explore why intravenous infusion remains the foundation of modern solid tumor treatment. Learn how ADCs, PD-1 immunotherapy, bispecific antibodies, and cell therapies are reshaping oncology in 2026.
CAR-T Therapy for Head and Neck Cancer: Challenges, Clinical Progress, and Future Perspectives
July 15, 2026
Explore the latest advances in CAR-T cell therapy for head and neck squamous cell carcinoma (HNSCC), including mechanisms, clinical challenges, emerging therapeutic targets, and future treatment strategies.
How Is a Pituitary Tumor Treated? A Comprehensive Guide to Surgery, Medication, and Radiation Therapy
July 15, 2026
Learn how pituitary tumors are treated, including medication, minimally invasive surgery, radiation therapy, and combination treatment strategies for different types of pituitary adenomas.
PD-1 Drugs for Head and Neck Cancer: Globally Approved Therapies, Clinical Advances, and Future Development Trends
July 14, 2026
Explore globally approved PD-1 inhibitors for head and neck cancer, including pembrolizumab, nivolumab, toripalimab, clinical trials, combination therapies, and future immunotherapy developments.
Advances in HER3 ADC Development for Head and Neck Squamous Cell Carcinoma (HNSCC): Latest Clinical Research and Future Perspectives
July 14, 2026
Explore the latest advances in HER3 antibody-drug conjugates (HER3 ADCs) for head and neck squamous cell carcinoma (HNSCC), including biological rationale, leading drug candidates, clinical trials, and future treatment strategies.
What Advanced Cancer Therapies Are Available in China? Which International Patients Are They Suitable For?
July 13, 2026
Explore advanced cancer therapies available in China, including CAR-T cell therapy, immunotherapy, proton and heavy ion therapy, NanoKnife, cryoablation, and precision targeted therapy.
Current Status of Solid Tumor Treatment in China (2026): A Comprehensive Guide for International Patients Seeking Cancer Care in China
July 13, 2026
Discover the latest advances in solid tumor treatment in China, including CAR-T therapy, immunotherapy, precision oncology, proton therapy, and leading cancer hospitals for international patients.
What Is Hidden Behind ‘Low-Cost CAR-T’? Global Regulators Are Cracking Down
July 11, 2026
Learn why global regulators are cracking down on low-cost CAR-T therapy programs, the hidden risks behind gray-market cell therapies, and how patients can identify legitimate CAR-T treatment providers.
What Increases the Risk of Brain Tumors? Understanding the Main Risk Factors
July 10, 2026
Learn the major risk factors for brain tumors, including ionizing radiation, inherited genetic syndromes, age, family history, immune dysfunction, and the latest advances in brain tumor risk prediction and precision medicine.
Why Does the Epstein-Barr Virus Cause Nasopharyngeal Carcinoma? Understanding High-Risk Factors and Early Warning Signs
July 09, 2026
Learn how Epstein-Barr virus (EBV) contributes to nasopharyngeal carcinoma (NPC), discover high-risk factors, early warning signs, screening methods, and the latest advances in precision medicine and innovative therapies.
Which GBM Patients May Benefit from Bevacizumab?
July 08, 2026
Learn which glioblastoma (GBM) patients may benefit from bevacizumab, its clinical benefits, treatment approaches, side effects, and role in recurrent GBM management.
Follicular Lymphoma Treatment Enters the Immunotherapy Era: Bispecific Antibodies Are Rising
July 08, 2026
Why Are More Cancer Drugs Becoming Oral Therapies? The Current Landscape of Oral Targeted Therapy in China
July 08, 2026
Explore why oral targeted therapies are transforming modern oncology, how China’s innovative pharmaceutical industry is driving this shift, and what it means for long-term cancer management and international patients.
A Milestone for Targeted Protein Degradation: The World’s First PROTAC Drug Approved
July 06, 2026
The U.S. FDA has approved Vepdegestrant (Veppanu), the world’s first PROTAC therapy, for ER-positive, HER2-negative, ESR1-mutant advanced or metastatic breast cancer—marking a historic milestone for targeted protein degradation.
What Is the Difference Between Nasopharyngeal Cancer, Oropharyngeal Cancer, and Laryngeal Cancer? Understanding the Key Differences Among Three Head and Neck Cancers
July 03, 2026
Learn the key differences between nasopharyngeal cancer, oropharyngeal cancer, and laryngeal cancer, including their causes, symptoms, diagnosis, treatment, and advances in precision medicine.
Why Are Solid Tumors More Difficult to Treat Than Blood Cancers? Uncovering the Key Challenges Behind Cancer Therapy
July 02, 2026
Discover why solid tumors are significantly more difficult to treat than blood cancers, including the roles of the tumor microenvironment, immune evasion, tumor heterogeneity, drug delivery barriers, and emerging cancer therapies.
Why Are Trispecific Antibodies More Complex Than Bispecific Antibodies? Understanding the Design Logic Behind Trispecific Antibodies
July 02, 2026
Explore why trispecific antibodies are more complex than bispecific antibodies, including their design strategies, engineering challenges, clinical potential, and future role in cancer immunotherapy.
How Does the Dual-arm Structure of T-cell Engagers Work? Unveiling the Design Logic Behind T-cell Engagers
July 01, 2026
Discover how the dual-arm structure of T-cell engagers (TCEs) redirects T cells to attack cancer cells, and explore the engineering principles, advantages, challenges, and future of T-cell engager therapies.
Is a Trispecific Antibody Necessarily Better Than a Bispecific? An Analysis of Efficacy, Safety, and Future Applications
July 01, 2026
Explore the differences between trispecific antibodies and bispecific antibodies, including efficacy, safety, manufacturing complexity, and future applications in cancer immunotherapy.